$TFX (Teleflex Incorporated)

$TFX {{ '2016-07-29T05:30:37+0000' | timeago}} • Announcement

$TFX said its BoD declared a quarterly cash dividend of $0.34 per common share. The dividend is payable Sept. 15, 2016 to shareholders of record at the close of business on Aug. 15, 2016.

$TFX {{ '2018-01-02T14:56:01+0000' | timeago}} • Announcement

$TFX completed its senior leadership transition. Effective Jan. 1, 2018, Liam Kelly, who was previously President & COO, assumed the position of President & CEO. Mr. Kelly succeeds Benson Smith, who retired as CEO, effective Dec. 31, 2017. Mr. Smith will continue to serve as non-executive Chairman of the Board.

$TFX {{ '2017-12-12T15:30:39+0000' | timeago}} • Announcement

$TFX's respiratory division has signed a new group purchasing agreement with HealthTrust. The Respiratory Heaters & Accessories agreement which became effective Dec. 1, 2017, covers Teleflex's full line of Active Humidification, Non Invasive Ventilation (NIV), and High Flow Nasal Cannula Therapy (HFNCT) products.

$TFX {{ '2017-10-02T20:23:51+0000' | timeago}} • Announcement

$TFX completed the acquisition of NeoTract, Inc. for $1.1Bil. Under the terms of the agreement, $TFX acquired NeoTract for an upfront cash payment of $725MM at closing, and has agreed to pay up to an additional $375MM upon the achievement of certain commercial milestones related to sales through the end of 2020.

$TFX {{ '2017-09-05T13:19:54+0000' | timeago}} • Announcement

$TFX agreed to acquire NeoTract. The acquisition is expected to be slightly dilutive to adjusted EPS in 2017, however, $TFX does not expect to adjust its prior adjusted EPS range. During 2018, the acquisition is expected to be breakeven to adjusted EPS, with significant accretion thereafter, including $0.35-0.40 of adjusted EPS accretion in 2019.

$TFX {{ '2017-09-05T13:17:43+0000' | timeago}} • Announcement

$TFX agreed to acquire NeoTract in a transaction valued up to $1.1Bil. The BoDs of both Teleflex and NeoTract have unanimously approved the transaction. During 2017, NeoTract's revenues are expected to be $115-120MM, and anticipates revenues to grow at least 40% in 2018.

$TFX {{ '2017-09-05T13:13:57+0000' | timeago}} • Announcement

$TFX agreed to buy NeoTract Inc. in a transaction valued up to $1.1Bil. $TFX will buy NeoTract for an upfront cash payment of $725MM at closing, and up to an additional $375MM upon the achievement of certain commercial milestones related to sales through the end of 2020. This transaction is expected to close within the next 30 days.

$TFX {{ '2017-08-03T16:09:21+0000' | timeago}} • Announcement

$TFX's BoD declared a quarterly cash dividend of $0.34 per share of common stock. The dividend is payable on Sept. 15, 2017 to shareholders of record on Aug. 15, 2017.

$TFX {{ '2017-07-24T12:12:24+0000' | timeago}} • Announcement

$TFX said its Arrow Seldinger Arterial Catheterization Device received market clearance from the U.S. Food and Drug Administration (FDA). The new Seldinger Arterial Catheterization Device is indicated for short-term use. $TFX expects to launch the Arrow Seldinger Arterial Catheterization Device in US this year.

$TFX {{ '2017-05-15T11:14:58+0000' | timeago}} • Announcement

$TFX commenced the Phase I clinical study of RePlas, a lyophilized fresh frozen plasma product being developed in collaboration with the U.S. Army Medical Materiel Development Activity (USAMMDA). The early administration of plasma has an important role in reducing trauma mortality from uncontrolled bleeding (hemorrhage).

$TFX {{ '2017-05-08T12:46:37+0000' | timeago}} • Announcement

$TFX's BoD declared a quarterly cash dividend of $0.34 per share of common stock. The dividend is payable on June 15, 2017 to shareholders of record at the close of business on May 15, 2017.

$TFX {{ '2017-05-02T14:03:12+0000' | timeago}} • Announcement

$TFX announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its AC3 Optimus Intra-Aortic Balloon Pump (IABP). This device helps a weakened heart pump blood and can deliver IABP therapy to a broad range of patients, even those not previously considered candidates for IABP therapy.

$TFX {{ '2017-04-04T15:08:12+0000' | timeago}} • Announcement

Teleflex Medical Canada Inc., a unit of $TFX, has completed the acquisition of Pyng Medical Corp. Under the terms of the transaction, Pyng shareholders received US$0.302 in cash per common share. Pyng is now wholly-owned by Teleflex Canada.

$TFX {{ '2017-02-23T15:04:46+0000' | timeago}} • Announcement

$TFX's BoD declared a quarterly cash dividend of $0.34 per share of common stock. The dividend is payable on March 15, 2017 to shareholders of record on March 3, 2017.

$TFX {{ '2017-02-23T15:02:08+0000' | timeago}} • Announcement

$TFX said Benson Smith will retire from his position as CEO, effective on Dec. 31, 2017. Smith will continue to serve as its Chairman of the Board. Smith has been nominated to serve for another 3-year term if elected at 2017 annual meeting. Liam Kelly, who now serves as President and COO, will succeed Smith as CEO following his retirement.

$TFX {{ '2017-02-17T18:28:33+0000' | timeago}} • Announcement

$TFX completed its previously announced acquisition of $VASC. On Dec. 2, 2016, the two companies announced a definitive agreement for $TFX to buy all of the issued and outstanding shares of $VASC common stock for $56.00 per share, in cash.

$PGNX {{ '2017-02-16T14:24:33+0000' | timeago}} • Announcement

$PGNX will replace $CLMS in the S&P SmallCap 600 effective Feb. 21, 2017 as $CLMS is being taken private in a transaction expected to be completed soon. $SFLY will replace $VASC in the S&P SmallCap 600 effective Feb. 21, 2017, as $VASC is being acquired by $TFX.

$TFX {{ '2016-12-14T13:37:36+0000' | timeago}} • Announcement

$TFX acquisition of $VASC is currently being investigated by WeissLaw LLP, said $VASC. Ongoing investigation is on the possible breaches of fiduciary duty and other violations of law by $VASC's BoD in connection with the acquisition. Under the terms of agreement, $VASC shareholders will receive $56.00 in cash for each company's share.

$VASC {{ '2016-12-02T14:23:03+0000' | timeago}} • Announcement

$VASC agreed to be acquired by $TFX for purchase price of $56 per share in cash. The transaction implies an equity purchase price of $1Bil. The price is 38.4x the midpoint of preliminary 2017 EPS forecast of $1.44-1.48 and transaction value is 5.2x midpoint of preliminary 2017 revenue forecast of $183-187MM. The deal will close in 1H17.

$TFX {{ '2016-12-02T13:12:02+0000' | timeago}} • Announcement

$TFX acquires $VASC. The transaction is expected to create value for $TFX shareholders and to be accretive to adjusted EPS in 2017, including the impact of incremental interest expense associated with financing the transaction. $TFX expects the acquisition to provide approx. $0.50 in adjusted EPS accretion in FY18.

$TFX {{ '2016-12-02T13:08:40+0000' | timeago}} • Announcement

$TFX acquires $VASC for approx. $1Bil. Under the terms of the agreement, $TFX will acquire all of the issued and outstanding shares of $VASC common stock for $56 per share in cash. The transaction is expected to close during 1H17.

Recent Transcripts

TEAR (TearLab Corporation)
Monday, November 13 2017 - 9:30pm
ENDP (Endo International plc)
Thursday, November 9 2017 - 9:30pm
RGEN (Repligen Corporation)
Thursday, November 9 2017 - 1:30pm
SRDX (SurModics, Inc.)
Wednesday, November 8 2017 - 1:30pm
PCRX (Pacira Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
TBPH (Theravance Biopharma, Inc.)
Tuesday, November 7 2017 - 10:00pm
RTRX (Retrophin, Inc.)
Tuesday, November 7 2017 - 9:30pm
XRAY (DENTSPLY International Inc.)
Friday, November 3 2017 - 12:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, November 3 2017 - 12:00pm
MTD (Mettler-Toledo International Inc.)
Thursday, November 2 2017 - 9:00pm
RVNC (Revance Therapeutics, Inc.)
Thursday, November 2 2017 - 8:30pm
LIVN (LivaNova PLC)
Thursday, November 2 2017 - 1:00pm
TFX (Teleflex Incorporated)
Thursday, November 2 2017 - 12:00pm
OSUR (OraSure Technologies, Inc.)
Wednesday, November 1 2017 - 9:00pm
MASI (Masimo Corporation)
Tuesday, October 31 2017 - 8:30pm
IDXX (IDEXX Laboratories, Inc.)
Tuesday, October 31 2017 - 12:30pm
OFIX (Orthofix International N.V.)
Monday, October 30 2017 - 8:30pm
TNDM (Tandem Diabetes Care, Inc.)
Thursday, October 26 2017 - 8:30pm
IART (Integra LifeSciences Holdings Corporation)
Thursday, October 26 2017 - 12:30pm
NUVA (NuVasive, Inc.)
Tuesday, October 24 2017 - 8:30pm

AlphaGraphics you may like